Why Dose Availability Matters for Mounjaro vs Wegovy Success
Mounjaro vs Wegovy: Complete Dose Escalation Journey
Understanding the full dose progression is crucial when comparing Mounjaro and Wegovy for long-term weight management success. Both treatments require mandatory dose escalation over 16 weeks, starting with 0.25mg for the first four weeks, progressing to 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), and finally reaching the 2.4mg maintenance dose from week 17 onwards. This gradual escalation helps minimise gastrointestinal side effects whilst optimising therapeutic benefits. Having access to every dose from a single pharmacy ensures seamless treatment continuity without supply interruptions that could compromise your progress.
The key difference lies in their mechanisms of action rather than dosing schedules. Mounjaro (tirzepatide) works as a dual GIP and GLP-1 receptor agonist, potentially offering enhanced metabolic benefits, whilst Wegovy (semaglutide) focuses specifically on GLP-1 receptor activation. Both require the same escalation timeline, making dose availability equally critical for either choice. At EverydayMeds, we maintain comprehensive stock levels across all five doses, allowing patients to progress smoothly from initiation through long-term maintenance without pharmacy transfers or treatment gaps.
Mounjaro vs Wegovy: Transparent Pricing Across All Doses
Pricing transparency becomes essential when planning long-term treatment with either Mounjaro or Wegovy. Our Wegovy pricing starts with 0.25mg at £79.99, progressing to 0.5mg at £94.99, 1mg at £99.99, 1.7mg at £139.99, and maintenance 2.4mg at £209.99. New customers benefit from discount code FIRST40 applied at checkout, whilst returning customers use code DOSE25 for continued savings. This transparent pricing structure allows patients to budget effectively for their entire weight management journey without unexpected cost increases at higher doses.
We offer convenient bundle options to support different treatment approaches, including our Intro Trio (0.25mg, 0.5mg, 1mg) at £299.99 for smooth dose progression, and our Ultimate Stability Trio (three 2.4mg pens) at £649.99 for maintenance supply security. These bundles provide convenience through fewer orders and Reliable Supply continuity rather than cost savings. Whether choosing Mounjaro or Wegovy, having predictable pricing across all doses helps patients commit to the long-term treatment necessary for sustained weight management success.
Mounjaro vs Wegovy: Clinical Evidence and Trial Data
Both treatments have demonstrated significant efficacy in randomised controlled trials, though direct head-to-head comparisons are limited. Wegovy's evidence base includes the STEP trial programme, where patients achieved average weight reductions of approximately 15% at 68 weeks when combined with lifestyle interventions (Wilding et al., NEJM, 2021). The STEP trials consistently showed superior weight loss compared to placebo across different patient populations, including those with and without type 2 diabetes.
Mounjaro's clinical evidence stems from the SURMOUNT trial programme, demonstrating its dual GIP/GLP-1 mechanism in weight management contexts. However, comparing percentage weight loss figures between trials would be misleading due to different study designs, patient populations, and endpoints. Both treatments require prescription-only access following clinical assessment, and individual responses may vary significantly based on adherence to dietary and exercise recommendations alongside medication use.
How Wegovy and Mounjaro Work: Mechanism Differences
Understanding how these treatments work helps explain why dose availability matters for optimal outcomes. Wegovy (semaglutide) functions as a GLP-1 receptor agonist, mimicking the natural incretin hormone that regulates blood sugar and appetite. It works primarily by slowing gastric emptying, enhancing satiety signals to the brain, and reducing food cravings between meals. This mechanism helps patients feel fuller for longer periods after eating smaller portions, supporting adherence to reduced-calorie diets. Mounjaro (tirzepatide) combines GLP-1 effects with glucose-dependent insulinotropic polypeptide (GIP) receptor activation, potentially offering enhanced metabolic benefits through this dual pathway approach. Both medications require gradual dose escalation to optimise therapeutic effects whilst minimising gastrointestinal tolerance issues that could lead to treatment discontinuation.
Mounjaro vs Wegovy: Streamlined Ordering Process
Accessing either Mounjaro or Wegovy through EverydayMeds involves a straightforward three-step process designed for convenience and safety. Patients complete a comprehensive three-minute online clinical assessment covering medical history, current medications, weight management goals, and relevant health conditions. Our qualified prescribers review applications within standard three working days, with express 24-hour review available for urgent requirements. Once approved, medications are dispatched via next-day delivery using specialised cold-chain packaging to maintain optimal storage temperatures throughout transit. This process ensures both treatments remain effective whilst providing rapid access to prescribed doses. Our GPhC registration (#9012878) ensures pharmaceutical standards and regulatory compliance throughout the supply chain.
Storage and Practical Considerations for Mounjaro vs Wegovy
Storage requirements differ slightly between these treatments, potentially influencing choice for frequent travellers. Wegovy offers superior storage flexibility, remaining stable at room temperature (below 30°C) for up to six weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both require initial refrigeration at 2-8°C and use similar pre-filled FlexTouch pen systems for weekly subcutaneous injection. The dose escalation schedule remains identical regardless of choice, with mandatory progression through five dose levels over 16 weeks before reaching maintenance therapy. Patients must not skip doses or accelerate escalation, as this increases side effect risks and may compromise treatment tolerance. Proper injection technique training and rotation of injection sites help optimise comfort and medication absorption throughout the treatment journey.
Mounjaro vs Wegovy: Long-term Treatment Planning
Successful weight management with either Mounjaro or Wegovy requires long-term commitment extending well beyond initial dose escalation phases. Research indicates that stopping treatment typically results in weight regain, with patients regaining approximately two-thirds of lost weight within one year of discontinuation. This makes maintenance dose availability crucial for sustained outcomes. Having reliable access to 2.4mg maintenance supplies prevents treatment interruptions that could compromise hard-earned progress.
Planning for long-term treatment involves considering both clinical and practical factors when comparing Mounjaro vs Wegovy options. Storage convenience, injection tolerability, side effect profiles, and consistent pharmacy supply all influence treatment adherence over months or years. Our comprehensive stock management ensures patients can maintain their chosen treatment without switching providers, preserving continuity of care and medication records. This stability becomes particularly valuable as patients establish routines and build confidence with their selected treatment approach.
Complete Mounjaro vs Wegovy Support: Your Treatment Partner
Choosing between Mounjaro and Wegovy represents just the beginning of a comprehensive weight management journey requiring ongoing support and medication access. Both treatments are available through EverydayMeds with complete dose ranges in stock, transparent pricing, and professional prescriber oversight. Whether you select Mounjaro's dual-pathway approach or Wegovy's proven GLP-1 mechanism, our clinical team provides continuity throughout your escalation and maintenance phases. New customers can start their assessment today using discount code FIRST40, whilst existing patients benefit from code DOSE25 for continued treatment. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment and discover which treatment option aligns best with your weight management goals. Our commitment extends beyond medication supply to supporting long-term success through reliable access, professional guidance, and comprehensive care coordination.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
